Clinical trial · Interventional
Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction
Strategy Therapy on Early Phase Cancer Therapeutics-Related Cardiac Dysfunction Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators use the cancer registration system of National Cheng Kung University Hospital to timely screen and evaluate those patients having breast cancer or lymphoma to enroll patients to participate in this clinical trial. The investigators planned an earlier initiation of Sacubitril/Valsartan treatment on breast cancer and lymphoma patients before the chemotherapy, and starting therapeutic intervention by Sacubitril/Valsartan once the heart damage sign appeared via novel echocardiography. The investigators aim to assess the protective and therapeutic benefit of cardioprotective drugs on the cardiotoxicity of anti-cancer therapy.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Cardiotoxicity | — | UNRESOLVED | — |
| Chemotherapeutic Toxicity | — | UNRESOLVED | — |
| Heart Failure | — | UNRESOLVED | — |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Prevention therapy | Drug | — | UNRESOLVED |
| Rescue therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Prevention therapy
- description
- Sacubitril/Valsartan (25/80) mg twice a day for 1 year
- interventionNames
- Drug: Prevention therapy
- type
- NO_INTERVENTION
- label
- Conventional therapy
- description
- No intervention
- type
- NO_INTERVENTION
- label
- Global longitudinal strain (GLS) function decreased >15%, No intervention
- description
- With the value of GLS function via echocardiography study decreased \>15%, No intervention
- type
- EXPERIMENTAL
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who are newly diagnosed with breast cancer or lymphoma and never accepted anti-cancer therapy * Age 20-65 years old * Systolic blood pressure ≥ 110 mmHg Exclusion Criteria: * End-stage renal disease (estimated Glomerulus Filtration Rate \<15 mL/min/1.73 m2) * Echocardiography Baseline left ventricle ejection fraction \< 50% * Allergy history to angiotensin receptor blockers * Life expectancy \< 1 year * Pregnancy * Unwilling to participate in this clinical study
References
Publications (0)
Data not yet available